Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a shorter pill course beat chagas?

NCT ID NCT03672487

Disease control Sponsor: Tulane University School of Public Health and Tropical Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a shorter, lower-dose course of the drug benznidazole works as well as the standard longer treatment for women with Chagas disease. Researchers enrolled 87 women in Argentina who had recently given birth and were infected with the parasite. The goal was to see if the shorter treatment could reduce side effects while still controlling the infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Benznidazole
What this could lead to
If successful, this could offer a shorter, safer treatment option for women with Chagas disease, reducing side effects while still controlling the infection.
What could go wrong
This is a small, completed trial with only 87 participants, and the shorter course may not be as effective as the standard longer treatment. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

87 people

The number who actually took part.

Started

Jun 2019

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent from the mother. * T. cruzi seropositivity confirmed by at least two positive tests. * Live birth. Exclusion Criteria: * Women residing outside of the provinces of Chaco, Santiago del Estero, or Tucumán. * Previous trypanocide treatment (BZN or nifurtimox). * Female sterilization; no intention to use modern contraception methods during treatment. * Positive pregnancy test. * History of severe alcohol abuse within two years; renal insufficiency.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chagas disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chagas disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chagas disease

Contacts and locations

Locations

  • Institute for Clinical Effectiveness and Health Policy

    Buenos Aires, Argentina

  • Tulane School of Public Health and Tropical Medicine

    New Orleans, Louisiana, 70112, United States

  • University of California at San Diego

    San Diego, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.